Know Cancer

or
forgot password

A Prospective Randomized Trial of Regional Versus Systemic Continuous Gemcitabine Chemotherapy in the Treatment of Unresectable Pancreatic Cancer


N/A
18 Years
80 Years
Not Enrolling
Both
Unresectable Pancreatic Cancer

Thank you

Trial Information

A Prospective Randomized Trial of Regional Versus Systemic Continuous Gemcitabine Chemotherapy in the Treatment of Unresectable Pancreatic Cancer


Inclusion Criteria:



- Signed written informed consent

- Karnofsky score > 60,

- Expected survival > 3 months,

- Liver, kidney function and routine blood test within normal range

- No serious cardiopulmonary dysfunction

- No acute infection

Exclusion Criteria:

- Pregnant or lactating women

- Uncontrolled internal diseases

- Past or the presence of other malignancy

- Those who had received immunosuppressive therapy

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

overall surviva

Outcome Time Frame:

36 months

Safety Issue:

No

Principal Investigator

Guohong Han, MD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Xijing Hospital of Digestive Diseases, Fourth Military Medical University

Authority:

China: Ethics Committee

Study ID:

XHDD 003

NCT ID:

NCT01665625

Start Date:

August 2012

Completion Date:

February 2016

Related Keywords:

  • Unresectable Pancreatic Cancer
  • Pancreatic cancer
  • Intra-arterial infusion
  • Gemcitabine
  • Pancreatic Neoplasms

Name

Location